Ritiometan

Ritiometan

SCHEMBL867253

O=C(O)CSC(SCC(=O)O)SCC(=O)O

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.53
CYP2D6 P10635 2/20 0.53
HIF1A Q16665 1/20 0.53
ALKBH5 Q6P6C2 2/20 0.43
CDC25B P30305 3/20 0.39
PHGDH O43175 1/20 0.39
FFAR1 O14842 1/20 0.36
LDHA P00338 1/20 0.35
SRR Q9GZT4 1/20 0.35
LMNA P02545 1/20 0.35
SUCNR1 Q9BXA5 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
TSHR P16473 2/20 0.35
SLC22A6 Q4U2R8 1/20 0.35
BHMT Q93088 1/20 0.34
S100A4 P26447 1/20 0.34
MAP2K7 O14733 1/20 0.33
CDC25A P30304 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL503348 0.83 CYP2C19 (0.50) CYP2C19CYP2D6HIF1AALKBH5CDC25B
SCHEMBL8030361 0.78 CYP2D6 (0.45) CYP2C19CYP2D6HIF1AALKBH5PHGDH
SCHEMBL4655762 0.78
SCHEMBL589940 0.78
SCHEMBL9811047 0.76
SCHEMBL23931412 0.74 BHMT (0.42) CYP2C19CYP2D6HIF1AALKBH5PHGDH
SCHEMBL8998014 0.74 CYP2D6 (0.41) CYP2C19CYP2D6HIF1AALKBH5PHGDH
SCHEMBL28862415 0.74 CYP2D6 (0.41) CYP2C19CYP2D6HIF1AALKBH5PHGDH
SCHEMBL1578703 0.74 CYP2D6 (0.41) CYP2C19CYP2D6HIF1AALKBH5LMNA
SCHEMBL9619629 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12274830-B2 Nitric oxide inhalation therapy for infants with bronchiolitis BEYOND AIR LTD (IL) 2025-04-15 US claimed
US-20240173512-A1 METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS STREETERVILLE CAPITAL, LLC 2024-05-30 US claimed
US-11890421-B2 Methods for potentiating antimicrobial agents BEYOND AIR LTD (IL) 2024-02-06 US claimed
US-20200246573-A1 NITRIC OXIDE INHALATION THERAPY FOR INFANTS WITH BRONCHIOLITIS STREETERVILLE CAPITAL, LLC 2020-08-06 US claimed
US-9499587-B2 Gamma-AApeptides with potent and broad-spectrum antimicrobial activity UNIVERSITY OF SOUTH FLORIDA (US) 2016-11-22 US claimed
US-20150274782-A1 GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY UNIVERSITY OF SOUTH FLORIDA (US) 2015-10-01 US claimed
WO-2013112548-A1 GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY UNIVERSITY OF SOUTH FLORIDA (US) 2013-08-01 WO claimed
US-20260060822-A1 BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF UNIV WAKE FOREST HEALTH SCIENCES (US) 2026-03-05 US disclosed
US-20260014091-A1 COMPOSITIONS AND METHODS OF MAKING AND USE THEREOF OHIO STATE INNOVATION FOUNDATION (US) 2026-01-15 US disclosed
US-20250366978-A1 DEVICES AND METHODS OF MAKING AND USE THEREOF METHODIST HOSPITAL (US) 2025-12-04 US disclosed
US-20250366979-A1 DEVICES AND METHODS OF MAKING AND USE THEREOF METHODIST HOSPITAL (US) 2025-12-04 US disclosed
WO-2025128946-A1 DEVICES AND METHODS OF MAKING AND USE THEREOF THE METHODIST HOSPITAL (US) 2025-06-19 WO disclosed
EP-4548975-A2 NITRIC OXIDE INHALATION THERAPY FOR INFANTS WITH BRONCHIOLITIS Beyond Air Ltd (IL) 2025-05-07 EP disclosed
US-20040141922-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2004-07-22 US disclosed
US-6680047-B2 FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS AMERSHAM HEALTH AS (NO) 2004-01-20 US disclosed
US-20020102215-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-20020102217-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040141922-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 CYP2C19 4871/4885CYP2D6 4840/4885HIF1A 465/4885
US-20260014091-A1 COMPOSITIONS AND METHODS OF MAKING AND USE THEREOF ERBB3, ERBB2, EGFR CYP2C19 443/4885CYP2D6 1648/4885HIF1A 3123/4885
US-20260060822-A1 BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF PFKP, PBK, MYLK CYP2C19 3697/4885CYP2D6 3754/4885HIF1A 1457/4885
US-20150274782-A1 GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY ANPEP, DNPEP, ENPEP CYP2C19 2211/4885CYP2D6 3805/4885HIF1A 2628/4885
US-20020102215-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 CYP2C19 4874/4885CYP2D6 4855/4885HIF1A 751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.